β-blockade in heart failure: Basic concepts and clinical results

American Journal of Hypertension

Volumn 11, Issue 1 II S, 1998, Pages

  Packer, Milton ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

blockers; Carvedilol; Heart failure; Norepinephrine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NORADRENALIN;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; BIOCHEMISTRY; CLINICAL OBSERVATION; CONFERENCE PAPER; HEART FAILURE; HOSPITALIZATION; HUMAN; MORTALITY; PHYSIOLOGY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC OUTPUT, LOW; CLINICAL TRIALS; HUMANS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 0031892885     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00425-1     Document Type: Conference Paper

References (98)

1. Epstein SE, Braunwald E. The effect of β-adrenergic blockade on patterns of urinary sodium excretion studies in normal subjects and in patients with heart disease . Ann Intern Med. 75:1966;20-27.
2. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 41:1978;233-243.
3. Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
4. Bristow MR, Hershberger RE, Port JD, et al. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 82:(suppl D):1990;12-25.
5. 1-receptor down-regulation in heart failure . Circ Res. 59:1986;297-309.
6. Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathway in the intact failing human heart progressive receptor downregulation and subsensitivity to agonist response . Circulation. 74:1986;1290-1302.
7. Feldman AM, Cates AK, Vaezev WB, et al. Increase of the 40,000 mol wt pertussin toxin substrate (G protein) in the failing human heart. J Clin Invest. 82:1988;189-197.
8. Lau CP, Pun KK, Leung WH. Reduced stimulatory guanine nucleotide binding regulatory protein in idiopathic dilated cardiomyopathy. Am Heart J. 122:1991;1787-1788.
9. Neumann J, Schmitz W, Scholz H, et al. Increase in myocardial G proteins in heart failure. Lancet. ii:1988;936-937.
10. Ransnas LA, Hjalmarson A, Insel PA. Dilated cardiomyopathy is associated with an impaired activation of the stimulatory G-protein, Gs, by GTP in heart membranes (abst). Circulation. 78:(suppl II):1988;II178.
11. Forster C, Carter SL, Armstrong PW. α 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure. Can J Physiol Pharmacol. 67:1989;110-115.
12. 1-adrenergic receptors in rat heart. J Cardiovasc Pharmacol. 3:1981;522-531.
13. Bohm M, Diet F, Feiler G, et al. α-Adrenoreceptors and α-adrenoreceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 12:1988;357-364.
14. 1-adrenergic receptors on sarcolemma from normal subjects and patients with dilated cardiomyopathy characteristics and linkage to GTP-binding protein . Circ Res. 261:1989;4860-4867.
15. 1-Adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 247:1988;1039-1045.
16. 1 adrenergic activity in cardiomyopathic Syrian hamster. Am J Physiol. 260:1991;H80-H88.
17. 1-Adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol. 260:1991;H953-H956.
18. Knowlton KU, Michel MC, Itani M, et al. The α-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 268:1993;15374-15380.
19. 1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation. 84:1991;1732-1740.
20. Sen LY, O'Neill M, Marsh JD, Smith TW. Inotropic and calcium kinetic effects of calcium channel agonist and antagonist in isolated cardiac myocytes from cardio myopathic hamsters. Circ Res. 67:1990;599-608.
21. Bonthu S, Oddis CV, Finkel MS. Norepinephrine enhances nitric oxide production by cardiac myocytes (abst). J Invest Med. 43:(suppl 2):1995;212A.
22. Pinsky DJ, Yang Y, Aji W, et al. Nitric oxide induces apoptosis of adult rat cardiac myocytes (abst). Circulation. 92:(suppl B):1995;I565.
23. Zimmer HG, Kolbeck-Ruhmkorff C, Zierhut W. Cardiac hypertrophy induced by alpha and β-adrenergic receptor stimulation. Cardioscience. 6:1995;47-57.
24. Simons M, Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J. 109:1985;297-304.
25. Hasenfuss G, Holubarsch C, Blanchard EM, et al. Influence of isoproterenol on myocardial energetics experimental and clinical investigations . Basic Res Cardiol. 84:(suppl 1):1989;147-155.
26. Anversa P, Ricci R, Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy a review . J Am Coll Cardiol. 7:1986;1140-1149.
27. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload implications for prophylactic effects of β-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors . J Am Coll Cardiol. 19:1992;1622-1633.
28. Packer M, Gottlieb SS, Kessler PD. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure the basis of a new physiologic approach to control of arrhythmia . Am J Med. 80:1986;23-29.
29. Mulieri LA, Hasenfuss G, Leavitt HP, et al. Altered myocardial force-frequency relation in human heart failure. Circulation. 85:1991;1743-1750.
30. McDonald KM, Rector T, Carlyle PF, et al. Angiotensin-converting enzyme inhibition and β-adrenoceptor blockade regress established ventricular remodelling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 24:1994;1762-1768.
31. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol. 18:1991;1-3.
32. Bristow MR, Olsen S, Gilbert EM, et al. β-blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart (abst). J Am Coll Cardiol. 19:1992;146A.
33. Yusuf S, Peto R, Lewis J, et al. β-blockade during and after myocardial infarction an overview of the randomized trials . Prog Cardiovasc Dis. 27:1985;335-371.
34. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
35. Heilbrunn SM, Shah P, Bristow MR, et al. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 79:1989;483-490.
36. Hjemdahl P, Olsson G: Rebound phenomena following withdrawal of long-term β-adrenoceptor blockade. Acta Med Scand 1982;(suppl 665):43-47.
37. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. β-Adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 71:1993;23C-29C.
38. Di Lenarda A, Gilbert EM, Olsen SL, et al. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy (abst). J Am Coll Cardiol. 17:1991;142A.
39. Packer M, Meller J, Gorlin R, Herman MV. Clinical and hemodynamic tachyphylaxis to prazosin-mediated afterload reduction in severe congestive heart failure. Circulation. 59:1979;531-539.
40. Belch JJF, Budges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 65:1991;245-248.
41. Sobotka PA, Brottman MD, Weitz Z, et al. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med. 14:1993;643-647.
42. Sole MJ, Schimmer J, Golstein D, Li RK. Oxidative stress contributes to decompensation of the failing heart (abst). Circulation. 92:(suppl D):1995;I31.
43. Haider N, Narula J, Hajjar RJ, et al. Apoptosis in human explanted cardiomyopathic hearts suggests programmed progression of dilated cardiomyopathy (abst). Circulation. 92:(suppl D):1995;I724.
44. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98.
45. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs comparison with propranolol . Cardiovasc Res. 26:1992;518-525.
46. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 21:1993;221-227.
47. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 90:1993;6189-6193.
48. Patel MK, Chan P, Betteridge LJ, et al. Inhibition of human vascular smooth muscle cell proliferation by novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol. 25:1995;652-657.
49. Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after β-blockade treatment. J Am Coll Cardiol. 23:1994;1397-1404.
50. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term β-adrenergic blockade in severe heart failure. J Am Coll Cardiol. 18:1991;1059-1066.
51. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy a randomized, double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
52. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind, randomized study of bucindolol versus placebo . Am J Med. 88:1990;223-229.
53. Krum H, Sackner-Bernstein JD, Goldsmith R, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation. 92:1995;1499-1506.
54. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
55. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
56. Waagstein F, Caidahl K, Wallentin I, et al. Long-term β-blockade in dilated cardiomyopathy. Circulation. 80:1989;551-563.
57. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
58. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 92:1995;212-218.
59. Leung WH, Lau CP, Wong CK, et al. A double-blind crossover trial of labetalol in patients with idiopathic dilated cardiomyopathy (abst). Circulation. 80:(suppl II):1989;II118.
60. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new β-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 21:1993;1094-1100.
61. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
62. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
63. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol. 66:1990;843-848.
64. Eichhorn EJ, McGhie I, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol. 67:1991;67-73.
65. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol. 268:1995;R317-R323.
66. Marguiles KB, Hildebrand FL, Lerman A, et al. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
67. Goldsmith RL, Krum HL, Bigger JT Jr, et al. β-blockade increases parasympathetic activity in chronic heart failure (abst). Circulation. 88:(suppl D):1993;I102.
68. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma levels of endothelin reflect the long-term clinical and hemodynamic effects of β-blockade in patients with chronic heart failure (abst). J Am Coll Cardiol. 23:1994;172A.
69. Anderson JL, Rodier HE, Green LS. Comparative effects of β-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol. 51:1983;196-202.
70. Cleland JGF, Dargie HJ. Arrhythmias, catecholamines and electrolytes. Am J Cardiol. 62:1988;55A-59A.
71. Johansson BW. Effect of β-blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction. Am J Cardiol. 57:1986;34F-37F.
72. Cannon RO III, Cunnion RE, Parrillo JE, et al. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. J Am Coll Cardiol. 10:1987;1190-1200.
73. A randomized trial of propranolol in patients with acute myocardial infarction II. Morbidity results . JAMA. 250:1983;2184-2189.
74. A randomized trial of propranolol in patients with acute myocardial infarction I. Mortality results . JAMA. 247:1992;1707-1714.
75. Feuerstein GZ, Hamburger SA, Smith EF III, et al. Myocardial protection with carvedilol. J Cardiovasc Pharmacol. 19:(suppl 1):1992;S138-S141.
76. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1026.
77. Swedberg K, Hjalmarson A, Waagstein F, et al. Adverse effects of β-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 44:1980;134-142.
78. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet. i:1979;1364-1366.
79. Currie PJ, Kelly MJ, McKenzie A, et al. Oral β-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 3:1984;203-209.
80. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral β-blockade in congestive cardiomyopathy. Lancet. ii:1981;490-493.
81. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 2:1983;755-763.
82. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
83. Paolisso G, Gambardella A, Marasso G, et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J. 123:1992;103-110.
84. Fisher ML, Gottleib SS, Plotnick G, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease a randomized trial . J Am Coll Cardiol. 23:1994;943-950.
85. A randomized trial of β-blockade in heart failure The Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
86. Pollock SG, Lystash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 66:1990;603-607.
87. Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure. Part 2: Content, reliability, and the validity of a new measureThe Minnesota Living With Heart Failure (LWHF) Questionnaire . Heart Failure. 3:1987;198-209.
88. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
89. Bristow MR, Gilbert EM, Abraham WT, et al. Multicenter oral carvedilol heart failure assessment a six-month dose-response evaluation in class II-IV patients (abst) . Circulation. 92:(suppl B):1995;I142.
90. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Failure. 3:1997;173-179.
91. The β-Blocker Pooling Project (BBPP) subgroup findings from randomized trials in postinfarction patients . Eur Heart J. 9:1988;8-16.
92. Basu S, Senior R, Van der Does R, et al. Carvedilol reduces adverse cardiac events following acute myocardial infarction (abst). Circulation. 92:(suppl B):1995;I20.
93. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-510.
94. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose β-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 55:1985;471-475.
95. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
96. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of β-blocker therapy for chronic heart failure preclude long-term treatment? (abst) . Circulation. 92:(suppl D):1995;I395.
97. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
98. Packer M, Colucci WS, Sackner-Bernstein J, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise . Circulation. 94:1995;2793-2799.